Drug Profile

Research programme: antibody therapeutics - Alchemab

Alternative Names: Antibody therapeutics - Alchemab; Huntington’s disease therapeutics – Alchemab

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Frontotemporal dementia; Huntington's disease
No development reported Cancer; Neurodegenerative disorders

28 May 2025 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
28 May 2025 No recent reports of development identified for research development in Neurodegenerative-disorders in United Kingdom (Parenteral)
06 Apr 2023 Alchemab pipeline, April 2023: Introduction updated, Therapeutic area added, DC added, Indications added, Dev lines added, FET added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com